Febuxostat administration for the prevention of tumour lysis syndrome: A meta‐analysis-Reference-Cited by-同舟云学术

Febuxostat administration for the prevention of tumour lysis syndrome: A meta‐analysis

Published:2019-04-10 Issue: Volume: Page:
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Bellos Ioannis¹^ORCID,Kontzoglou Konstantinos²,Psyrri Amanda³,Pergialiotis Vasilios¹

Affiliation:

1. Laboratory of Experimental Surgery and Surgical Research N.S. Christeas Athens University Medical School, National and Kapodistrian University of Athens Athens Greece

2. 2nd Department of Propedeutic Surgery “Laikon” General Hospital, National and Kapodistrian University of Athens Athens Greece

3. Division of Oncology, 2nd Department of Internal Medicine Attikon University Hospital Athens Greece

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.12839

Reference31 articles.

1. Tumor Lysis Syndrome in Patients with Hematological Malignancies

2. Tumor lysis syndrome: A clinical review

3. Tumour lysis syndrome: new therapeutic strategies and classification

4. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-κB

5. Acute renal failure from xanthine nephropathy during management of acute leukemia

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumour lysis syndrome;Nature Reviews Disease Primers;2024-08-22

2. The contradictory role of febuxostat in ABCG2 expression and potentiating hypericin-mediated photodynamic therapy in colorectal cancers;Photochemical & Photobiological Sciences;2024-04-16

3. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel;Cancer Treatment Reviews;2023-11

4. Tumor Lysis Syndrome;JAP Academy Journal;2023-10-12

5. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022;International Journal of Clinical Oncology;2023-07-16